An siRNA knock-down of ANXA1 in the B16B16 cells reduced their invasive capability giving rise to idea that ANXA1 could also be a potential therapeutic target for metastatic cancers [82]. The gene discussed is ANXA1; the disease is metastatic malignant neoplasm.